Article
Novo Nordisk's semaglutide set to tackle obesity with hotly-anticipated FDA green light
Rating:
0.0
Views:
96
Likes:
1
Library:
1
With obesity widespread, undertreated and largely misunderstood, Novo Nordisk has been gunning to overhaul the field with semaglutide, a drug originally approved to treat diabetes. On Friday, it won its FDA green light.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value